🔗 Share this article The Global Health Body Issues Alert Over Severe Shortage of Weight-Loss Medications Under one in 10 patients that would benefit from obesity jabs including Wegovy can access them, states the global health agency as it releases its first recommendations on the medications. Considering more than one billion people worldwide now obese, it is advocating for broader and more equitable availability to GLP-1 medication. Per projections, more than two billion will be obese by 2030 unless action is taken. "Our new guidance affirms that excess weight is a lifelong illness that can be treated with holistic and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to widespread access to the injections that can aid individuals in losing considerable body mass, explains the body. Skinny Jab Scarcity Even in the current most favorable scenario, the manufacturing of such drugs could only cover approximately 100 million people – fewer than 10% of eligible patients, according to the WHO. The recommendation calls on governments and firms to widen access, by measures including voluntary licensing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is set to lapse in several countries in 2026. How Obesity Drugs Function The injections mimick a biological compound to slow digestion, curb appetite and boost feelings of fullness so people consume fewer calories. Individuals typically begin shedding pounds after several weeks of starting on the regular doses. Evidence points to people may put most of the weight back on within a year of stopping the treatment, when their typical appetite come back. Being above a healthy weight elevates your chance for developing medical conditions, like diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity concerns individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the WHO.
Under one in 10 patients that would benefit from obesity jabs including Wegovy can access them, states the global health agency as it releases its first recommendations on the medications. Considering more than one billion people worldwide now obese, it is advocating for broader and more equitable availability to GLP-1 medication. Per projections, more than two billion will be obese by 2030 unless action is taken. "Our new guidance affirms that excess weight is a lifelong illness that can be treated with holistic and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus. Significant expense, insufficient output, and logistical bottlenecks are significant obstacles to widespread access to the injections that can aid individuals in losing considerable body mass, explains the body. Skinny Jab Scarcity Even in the current most favorable scenario, the manufacturing of such drugs could only cover approximately 100 million people – fewer than 10% of eligible patients, according to the WHO. The recommendation calls on governments and firms to widen access, by measures including voluntary licensing. Exclusive production rights on semaglutide – the main ingredient of a leading brand – is set to lapse in several countries in 2026. How Obesity Drugs Function The injections mimick a biological compound to slow digestion, curb appetite and boost feelings of fullness so people consume fewer calories. Individuals typically begin shedding pounds after several weeks of starting on the regular doses. Evidence points to people may put most of the weight back on within a year of stopping the treatment, when their typical appetite come back. Being above a healthy weight elevates your chance for developing medical conditions, like diabetes, cardiovascular issues, brain attack, and certain cancers. Obesity concerns individuals in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the WHO.